FSHD

BASEL — September 8, 2026 Novartis announced that its global Phase III HARBOR study of delpacibart etedesiran (del-desiran) in...

SAN FRANCISCO, Calif., June 26, 2026 Epicrispr Biotechnologies announced encouraging interim Phase 1/2 clinical trial results for EPI-321, its...

BOSTON, MA, June 11, 2026 Curium Group, in collaboration with PeptiDream Inc. and PDRadiopharma Inc., has announced the completion...

BASEL, Switzerland, June 11, 2026 Novartis has announced positive results from the FORTITUDE Phase I/II clinical study evaluating delpacibart...

SAN DIEGO, Calif., February 26, 2026 Avidity Biosciences, Inc. (Nasdaq: RNA) announced that it will present one oral and...